Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
Holding GKOS?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.38Last Year’s EPS
-$0.63Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: 14.84%
|Next Earnings Date:Feb 19, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with record sales and strong growth in both U.S. and international glaucoma markets, alongside promising clinical trial results for Epioxa. These achievements are somewhat tempered by challenges in corneal health revenues and ongoing reimbursement hurdles for iDose TR.Company Guidance
In the recent earnings call for Glaukos Corporation, the company reported record third-quarter consolidated net sales of $96.7 million, marking a 24% increase compared to the same period last year. As a result, Glaukos raised its full-year 2024 net sales guidance range to $377 million to $379 million, up from the previous range of $370 million to $376 million. The U.S. glaucoma franchise achieved record third-quarter sales of $51.6 million, experiencing a 35% year-over-year growth driven by the iDose TR and the iStent portfolio. The international glaucoma franchise reported sales of $24.5 million with a 21% year-over-year growth, while the Corneal Health franchise recorded sales of $20.6 million, reflecting a 5% growth. The company also highlighted progress on regulatory and reimbursement fronts, including the implementation of a permanent J-code for iDose TR and advancements in professional fee coverage with Medicare Administrative Contractors.Record Third Quarter Sales
Glaukos reported record third quarter consolidated net sales of $96.7 million, up 24% compared to the previous year, driven by U.S. and international glaucoma franchises.
U.S. Glaucoma Franchise Growth
The U.S. glaucoma franchise delivered record third quarter sales of $51.6 million, with a 35% year-over-year increase, driven by iDose TR and iStent portfolio growth.
International Glaucoma Franchise Expansion
International glaucoma sales reached $24.5 million, marking a 21% year-over-year growth, supported by broad-based expansion and favorable French CEPS agreement.
Positive Epioxa Phase III Trial Results
Announced positive top-line results from the second Phase III pivotal study for Epioxa, meeting primary efficacy endpoints and supporting an NDA submission by the end of 2024.
Strong Financial Position
Announced the redemption of $57.5 million in convertible senior notes, contributing to a strong capital position and reduced future cash interest expenses.
---
GKOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GKOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $131.38 | $127.86 | -2.68% |
| Jul 31, 2024 | $117.17 | $117.61 | +0.38% |
| May 01, 2024 | $98.91 | $105.03 | +6.19% |
| Feb 21, 2024 | $92.79 | $91.46 | -1.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Glaukos (GKOS) report earnings?
Glaukos (GKOS) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Glaukos (GKOS) earnings time?
Glaukos (GKOS) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GKOS EPS forecast?
GKOS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.38.
---